Hypoxia drives breast tumor malignancy through a TET-TNFα-p38-MAPK signaling axis

Cancer Research

Volumn 75, Issue 18, 2015, Pages 3912-3924

  Wu, Min Zu ^a   Chen, Su Feng ^b,c   Nieh, Shin ^c   Benner, Christopher ^a   Ger, Luo Ping ^d,e   Jan, Chia Ing ^b   Ma, Li ^a   Chen, Chien Hung ^a   Hishida, Tomoaki ^a   Chang, Hong Tai ^e   Lin, Yaoh Shiang ^c,e   Montserrat, Nuria ^f   Gascon, Pedro ^f   Sancho Martinez, Ignacio ^a   Belmonte, Juan Carlos Izpisua ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^e KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; CD24 ANTIGEN; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE P38; TEN ELEVEN TRANSLOCATION 1; TEN ELEVEN TRANSLOCATION 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNCLASSIFIED ENZYME; 5-HYDROXYMETHYLCYTOSINE; CYTOSINE; DIOXYGENASE; DNA BINDING PROTEIN; HIF1A PROTEIN, HUMAN; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MIXED FUNCTION OXIDASE; ONCOPROTEIN; TET1 PROTEIN, HUMAN; TET3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; BREAST TUMOR INITIATING CELL; CANCER PROGNOSIS; CELLS BY BODY ANATOMY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; MAJOR CLINICAL STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR HYPOXIA; TUMOR MALIGNANCY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; CELL HYPOXIA; CHROMATIN IMMUNOPRECIPITATION; CYTOLOGY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CYTOSINE; DIOXYGENASES; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942937379     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3208     Document Type: Article

References (53)

1. Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity [corrected]. Nat Rev Clin Oncol 2010;7:139-47.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
3. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
4. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-8.
5. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are sparedbycisplatin treatment. Proc Natl Acad Sci USA 2009;106:16281-6.
6. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-11.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
8. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67.
9. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
10. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73.
11. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007;7:791-9.
12. Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells. Trends Mol Med 2012;18:534-43.
13. Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, et al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-9.
14. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72.
15. Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011;71:634-9.
16. Wu MZ, Tsai YP, Yang MH, Huang CH, Chang SY, Chang CC, et al. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol Cell 2011;43:811-22.
17. Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett 2013;341:80-96.
18. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
19. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011;333:1300-3.
20. Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev 2011;25:2436-52.
21. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010;468:839-43.
22. Gu TP, Guo F, Yang H, Wu HP, Xu GF, Liu W, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011;477:606-10.
23. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 2004;202:265-73.
24. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;9:357-9.
25. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010;38:576-89.
26. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductorpackage for differential expression analysis of digital gene expression data. Bioinfor-matics 2010;26:139-40.
27. Lin YC, Benner C, Mansson R, Heinz S, Miyazaki K, Miyazaki M, et al. Global changes in the nuclear positioning of genes and intra- and inter-domain genomic interactions that orchestrate B cell fate. Nat Immunol 2012;13:1196-204.
28. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol 2010;12:982-92.
29. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40:499-507.
30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
31. Feng W, Gentles A, Nair RV, Huang M, Lin Y, Lee CY, et al. Targeting unique metabolic properties of breast tumor initiating cells. Stem Cells 2014;32:1734-45.
32. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008;68:3243-50.
33. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFbeta/TNF (alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 2011;71:4707-19.
34. Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013;13:727-38.
35. Takasaki T, Akiba S, Sagara Y, Yoshida H. Histological and biological characteristics of microinvasion in mammary carcinomas < or = 2 cm in diameter. Pathol Int 1998;48:800-5.
36. Kalhor R, Tjong H, Jayathilaka N, Alber F, Chen L. Genome architectures revealed by tethered chromosome conformation capture and population-based modeling. Nat Biotechnol 2011;30:90-8.
37. Tsuchihara K, Suzuki Y, Wakaguri H, Irie T, Tanimoto K, Hashimoto S, et al. Massive transcriptional start site analysis of human genes in hypoxia cells. Nucleic Acids Res 2009;37:2249-63.
38. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005;15:11-8.
39. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005;19:362-70.
40. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24-phenotype. BMC Cancer 2010;10:411.
41. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krish-namurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009;69:4116-24.
42. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 2004;100:499-506.
43. Whyte J, Bergin O, Bianchi A, McNally S, Martin F. Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 2009;11:209.
44. Zer C, Sachs G, Shin JM. Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-alpha signaling. Physiol Genomics 2007;31:343-51.
45. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010;7:150-61.
46. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013;501:328-37.
47. Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, et al. The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet 2012;8:e1002517.
48. Huang H, Jiang X, Li Z, Li Y, Song CX, He C, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA 2013;110:11994-9.
49. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012;150:1135-46.
50. Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metallo-proteinases. Cell Rep 2012;2:568-79.
51. Shahrzad S, Bertrand K, Minhas K, Coomber BL. Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2007;2:119-25.
52. Liu Q, Liu L, Zhao Y, Zhang J, Wang D, Chen J, et al. Hypoxia induces genomic DNA demethylation through the activation of HIF-1alpha and transcriptional upregulation of MAT2A in hepatoma cells. Mol CancerTher 2011;10:1113-23.
53. Oeztuerk-Winder F, Ventura JJ. The many faces of p38 mitogen-activated protein kinase in progenitor/stem cell differentiation. Biochem J 2012;445:1-10.